Skip to main content
. 2021 Mar 13;11(9):2859–2879. doi: 10.1016/j.apsb.2021.03.020

Figure 7.

Figure 7

FLZ administration inhibits intestinal inflammation and neuroinflammation by inhibiting TLR4/MyD88/NF-κB signaling pathway. (A) Representative Western blot brands of TLR4, MyD88, p-IκB-α, IκB-α, and NF-κB in SN. (B)–(F) The density analysis results of TLR4, MyD88, p-IκB-α, IκB-α, and NF-κB in SN. (G) ELISA levels of TNF-α in SN. (H) Representative Western blot brands of TLR4, MyD88, p-IκB-α, IκB-α, and NF-κB in colon. (I)–(M) The density analysis results of TLR4, MyD88, p-IκB-α, IκB-α, and NF-κB in colon. (N) ELISA levels of TNF-α in colon. (O) Representative captures of immunofluorescence of TLR4 in SN. (P) Numbers of TLR4+ cells in SN. (Q) Representative captures of immunofluorescence of TLR4 in colon. (R) Numbers of TLR4+ cells in colon. (S) The mRNA expression of Tlr4 in SN and colon. (T) The mRNA expression of Tnf in SN and colon. In (B)–(F) and (I)–(M), n = 4 for each group. In (G) and (N), n = 8 for each group. In (P) and (R), n = 5 for each group. In (S)–(T), n = 3 for each group. Data are presented as mean ± SD. #P < 0.05, ##P < 0.01, ###P < 0.001 versus the Control group; ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 versus the Rotenone group.